Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05335161 |
Other study ID # |
IRB-2022-375 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
Phase 1
|
First received |
|
Last updated |
|
Start date |
September 1, 2022 |
Est. completion date |
January 31, 2024 |
Study information
Verified date |
August 2022 |
Source |
Purdue University |
Contact |
Bruno Tesini Roseguini, Ph.D. |
Phone |
7654962612 |
Email |
brosegui[@]purdue.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The goal of the proposed pilot study is to evaluate the feasibility of a new leg heat therapy
system treatment for patients with lower extremity PAD. The new system is comprised of
leg-length water circulating pads surrounded by a separate pneumatic compression outer
garment that compresses the pads against the skin for efficient heat transfer. The new leg
garment is easily closed with a zipper. The air chambers automatically adjust the amount of
air inflation enabling use of the garment independent of patient leg size. Six patients with
PAD will be asked to complete daily (90 min/day) home-based leg HT for 12 weeks using the
newly developed system. The primary study outcome is the change from baseline in walking
performance on the 6-minute walk test at the 12-week follow-up. Secondary outcomes include
plantar flexion power, as assessed using isokinetic dynamometry, sit-to-stand muscle power
and perceived quality of life.
Description:
Lower-extremity PAD is a manifestation of systemic atherosclerosis associated with increased
risk of cardiovascular morbidity and mortality, diminished quality of life, physical
functioning and psychological well-being. In 2015, an estimated 236 million people worldwide,
most between 65 and 69 years of age, were living with PAD. Home-based leg heat therapy (HT)
is emerging as a potential effective and practical treatment to increase leg blood flow and
improve walking performance in patients with symptomatic PAD. In the first randomized
sham-controlled trial to examine the benefits of supervised leg HT in patients with
symptomatic PAD (90 min, 3 days/week for 6 weeks), we demonstrated that patients assigned to
the leg heating group displayed a clinically meaningful improvement in perceived physical
functioning. Building upon these findings, we recently completed a NIH-sponsored randomized
clinical trial to examine the safety, tolerability, and effectiveness of home-based,
unsupervised leg HT (90 min, 7 days/week for 8 weeks) in 34 patients with symptomatic PAD.
Patients randomized to the HT group displayed an increase in 6-minute walk from baseline of
23 meters after 8 weeks of treatment, which is clinically meaningful for PAD patients.
Importantly, home-based leg HT was also found to be safe (no skin injury), well-tolerated,
and patient compliance was surprisingly high (96% completion of the prescribed treatment
sessions).
Heat packs, electric heating pads, and electric blankets are widely available, but have high
risk of contact burns, particularly in patients with peripheral neuropathy that is commonly
associated with diabetes mellitus and PAD. An assembly of individual pads is difficult to
apply and skin contact is unreliable. Water-circulating pads have been found to be safer than
electric devices because they provide more reliable thermostatic control. PAD patients with
diffuse bilateral disease often accompanied by neuropathy need a reliable system that is
simple to operate, easy to put on, covers the entirety of both lower limbs and safely
provides HT while avoiding skin injury. Currently, there is no commercially-available HT
system for home-based therapy in elderly individuals, despite the documented benefits
associated with repeated HT. To address this unmet clinical need, Aquilo Sports is developing
a system that will monitor skin temperature and have an integrated shut-off feature to
prevent skin burns, and record treatment sessions to confirm patient compliance. The system
has undergone extensive independent validation testing and has been widely adopted by
professional athletes. The garment is easily closed with a zipper and auto-adjusts
pneumatically to different leg sizes.
Our objective is to establish evidence to support the safety and feasibility of the
redeveloped Aquilo system during repeated home-based treatment in patients with PAD. Our
approach to testing our hypothesis will be to ask 6 patients with PAD to undergo daily
home-based leg HT (90 min/day, 7 days/week) for 12 weeks. The length of the intervention (12
weeks) was selected as it is similar to: 1) the duration of previous studies with other HT
modalities showing beneficial effects in patients with PAD, 2) the recommended minimal
duration of exercise training interventions, the gold standard treatment for PAD.
The primary study outcome is the change from baseline in walking performance on the 6-minute
walk test at the 12-week follow-up. Secondary outcomes include plantar flexion power, as
assessed using isokinetic dynamometry, sit-to-stand muscle power and perceived quality of
life.The study coordinator will call patients weekly to record the occurrence of adverse
events.